Diagnosing small bowel carcinoid tumor in a patient with oligometastatic prostate cancer imaged with PSMA-Targeted [18F]DCFPyL PET/CT: Value of the PSMA-RADS-3D Designation
暂无分享,去创建一个
Steven P. Rowe | Kenneth J. Pienta | Michael A. Gorin | Alan W. Partin | Seohyun Kim | Martin G. Pomper | Emmanuel S. Antonarakis | K. Pienta | A. Partin | M. Pomper | M. Allaf | E. Antonarakis | M. Gorin | Pamela T. Johnson | E. Shenderov | S. Rowe | Eugene Shenderov | Mohamad E. Allaf | Seohyun Kim
[1] Uwe Haberkorn,et al. Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging , 2017, European Journal of Nuclear Medicine and Molecular Imaging.
[2] Steven P Rowe,et al. Proposal for a Structured Reporting System for Prostate-Specific Membrane Antigen–Targeted PET Imaging: PSMA-RADS Version 1.0 , 2017, The Journal of Nuclear Medicine.
[3] K. Pienta,et al. PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges , 2016, Prostate Cancer and Prostatic Disease.
[4] R. Kumar,et al. Metastatic poorly differentiated prostatic carcinoma with neuroendocrine differentiation: negative on 68Ga-PSMA PET/CT. , 2015, Clinical nuclear medicine.
[5] Zsolt Szabo,et al. Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT , 2015, Annals of Nuclear Medicine.